Thus, targeting the IL-33-enhanced-CXCR4 regulatory circuit attenuates tumor aggressiveness and provides a potential therapeutic option for improving the prognosis in HNSCC patients. This evidence concerns the gene IL33 and head and neck squamous cell carcinoma.